scholarly journals Discovery of Highly Potent Multidrug Resistance (MDR) Reversal Agents: Aminosulfonylaryl Isoxazole Derivatives

2009 ◽  
Vol 30 (4) ◽  
pp. 779-780 ◽  
ChemInform ◽  
2009 ◽  
Vol 40 (36) ◽  
Author(s):  
Young Taek Han ◽  
Eun Kyung Kim ◽  
Eun Ae Kim ◽  
Eun Seon Kim ◽  
Dae Kyong Kim ◽  
...  

2010 ◽  
Vol 53 (14) ◽  
pp. 5108-5120 ◽  
Author(s):  
Pu Yong Zhang ◽  
Iris L. K. Wong ◽  
Clare S. W. Yan ◽  
Xiao Yu Zhang ◽  
Tao Jiang ◽  
...  

Pharmaceutics ◽  
2018 ◽  
Vol 10 (3) ◽  
pp. 127 ◽  
Author(s):  
Daniel Dantzic ◽  
Pawan Noel ◽  
Fabrice Merien ◽  
Dong-Xu Liu ◽  
Jun Lu ◽  
...  

Multidrug resistance (MDR) is a major hurdle which must be overcome to effectively treat cancer. ATP-binding cassette transporters (ABC transporters) play pivotal roles in drug absorption and disposition, and overexpression of ABC transporters has been shown to attenuate cellular/tissue drug accumulation and thus increase MDR across a variety of cancers. Overcoming MDR is one desired approach to improving the survival rate of patients. To date, a number of modulators have been identified which block the function and/or decrease the expression of ABC transporters, thereby restoring the efficacy of a range of anticancer drugs. However, clinical MDR reversal agents have thus far proven ineffective and/or toxic. The need for new, effective, well-tolerated and nontoxic compounds has led to the development of natural compounds and their derivatives to ameliorate MDR. This review evaluates whether synthetically modifying natural compounds is a viable strategy to generate potent, nontoxic, ABC transporter inhibitors which may potentially reverse MDR.


2020 ◽  
Vol 95 ◽  
pp. 103546 ◽  
Author(s):  
Yao Zhang ◽  
Run-Zhu Fan ◽  
Jun Sang ◽  
Yi-Jing Tian ◽  
Jia-Qi Chen ◽  
...  

2020 ◽  
Vol 10 (2) ◽  
pp. 327-343 ◽  
Author(s):  
Senling Feng ◽  
Huifang Zhou ◽  
Deyan Wu ◽  
Dechong Zheng ◽  
Biao Qu ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jerónimo Laiolo ◽  
Priscila Ailin Lanza ◽  
Oscar Parravicini ◽  
Cecilia Barbieri ◽  
Daniel Insuasty ◽  
...  

AbstractP-gp-associated multidrug resistance is a major impediment to the success of chemotherapy. With the aim of finding non-toxic and effective P-gp inhibitors, we investigated a panel of quinolin-2-one-pyrimidine hybrids. Among the active compounds, two of them significantly increased intracellular doxorubicin and rhodamine 123 accumulation by inhibiting the efflux mediated by P-gp and restored doxorubicin toxicity at nanomolar range. Structure–activity relationships showed that the number of methoxy groups, an optimal length of the molecule in its extended conformation, and at least one flexible methylene group bridging the quinolinone to the moiety bearing the pyrimidine favored the inhibitory potency of P-gp. The best compounds showed a similar binding pattern and interactions to those of doxorubicin and tariquidar, as revealed by MD and hybrid QM/MM simulations performed with the recent experimental structure of P-gp co-crystallized with paclitaxel. Analysis of the molecular interactions stabilizing the different molecular complexes determined by MD and QTAIM showed that binding to key residues from TMH 4–7 and 12 is required for inhibition.


2021 ◽  
Author(s):  
Jerónimo Laiolo ◽  
Priscila Ailin Lanza ◽  
Oscar Parravicini ◽  
Cecilia Barbieri ◽  
Daniel Insuasty ◽  
...  

Abstract P-gp-associated multidrug resistance (MDR) is a major impediment to the success of chemotherapy. With the aim of finding non-toxic and effective P-gp inhibitors, we investigated a panel of quinolin-2-one-pyrimidine hybrids. Among the active compounds, two of them significantly increased intracellular doxorubicin and rhodamine 123 accumulation by inhibiting the efflux mediated by P-gp and restored doxorubicin toxicity at nanomolar range. Structure-activity relationships showed that the number of methoxy groups, an optimal length of the molecule in its extended conformation, and at least one flexible methylene group bridging the quinolinone moiety favored the inhibitory potency of P-gp. The best compounds showed a similar binding pattern and interactions to those of doxorubicin and tariquidar, as revealed by MD and hybrid QM/MM simulations performed with the recent experimental structure of P-gp co-crystallized with paclitaxel. Analysis of the molecular interactions stabilizing the different molecular complexes determined by MD and QTAIM showed that binding to key residues from TMH 4–7 and 12 is required for inhibition.


Sign in / Sign up

Export Citation Format

Share Document